The United Kingdom and the United States have agreed to a important bilateral deal that will keep zero import taxes on British drug products going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This commitment secures that import taxes on these vital goods will be held at nothing for a period of 36 months.
This agreement is in response to recent warnings to dramatically increase import taxes on branded drug imports, with figures mentioned reaching 100%.
"This arrangement between the United Kingdom reinforces the international landscape for innovative medicines and introduces long-overdue balance to American-British drug exports," a release said.
Trade Impact
Medicines constitute one of the UK's biggest export categories to the America, which is by far the largest destination for leading UK drugmakers.
Export figures indicate that in the one-year period prior to September, the UK sold drugs totaling over eleven billion pounds to the US. This figure represented a significant portion of British export trade in that period.
"This deal safeguards jobs, boosts capital expenditure and sets the stage for the UK to become a global hub for life sciences," a government official remarked.
Detailed British Pledges
The deal includes several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds were more than twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were heightened by claims that US patients were paying significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward American operations.
A senior figure stated that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the last ten years.
